News & Updates
Filter by Specialty:
Enfortumab vedotin-pembrolizumab beats chemo as 1L Tx for bladder cancer
03 Nov 2023
byAudrey Abella
In the phase III EV-302/KEYNOTE-A39 trial, the combination of enfortumab vedotin and pembrolizumab (EV+P) had a significant survival advantage over chemotherapy in the first-line treatment of patients with locally advanced metastatic urothelial carcinoma (la/mUC).
Enfortumab vedotin-pembrolizumab beats chemo as 1L Tx for bladder cancer
03 Nov 2023
Histologic inflammation of IBD a risk factor for serious infections
03 Nov 2023
Among individuals with inflammatory bowel disease (IBD), histologic inflammation appears to contribute to an increased risk of serious infections such as sepsis, according to a study, suggesting that achieving remission may reduce infections in IBD.
Histologic inflammation of IBD a risk factor for serious infections
03 Nov 2023
Biomarker-driven therapies superior to standard care in breast cancer
02 Nov 2023
Patients with breast cancer may gain greater therapeutic advantages from biomarker-driven than standard-of-care therapies, suggests a study.
